Elevation Pharmaceuticals has reported positive efficacy and safety results from its Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizser (GOLDEN-1) study of EP-101 in chronic obstructive pulmonary disease (COPD) patients.

The Phase IIb, randomised, placebo-controlled study was designed to assess the pharmacokinetics, safety and efficacy of EP-101 in 140 patients with moderate-to-severe COPD.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

According to the study results, EP-101, an inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an investigational eFlow nebuliser, demonstrated a rapid onset, dose-related, statistically significant improvement in lung function compared to placebo.

Elevation Pharmaceuticals senior vice president and chief medical officer Dr Ahmet Tutuncu said; "The positive outcome of this large Phase 2b study is an important milestone towards our goal of significantly elevating the standard of care for COPD patients who require nebulizer delivery of their medicines."

The 25mcg, 50 mcg, 100 mcg and 200 mcg doses of EP-101 administered once daily for seven days provided a rapid onset of action, short treatment time and a strong magnitude of bronchodilation compared to placebo.

See Also:

The bronchodilatory improvements on day seven as assessed by 24-hour forced expiratory volume in one second (FEV1) and the FEV1 AUC (0-12 hours and 12-24 hours) were dose-dependent, statistically significant (p<0.001) at all doses compared to placebo, and clinically meaningful at several doses compared to placebo, according to the study data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

EP-101 was well tolerated at all doses, and reported a similar adverse event profile compared to placebo and to ipratropium, but tended to be higher than treatment with tiotropium.

The company expects to begin a second Phase IIb study in the fourth quarter of 2012 to select the dose for its Phase III studies, which are scheduled to commence in the second half of 2013.